Article
Gastroenterology & Hepatology
Georg Semmler, Teresa Binter, Karin Kozbial, Philipp Schwabl, Stefanie Hametner-Schreil, Alberto Zanetto, Sabrina Gavasso, David Chromy, David J. M. Bauer, Benedikt Simbrunner, Bernhard Scheiner, Theresa Bucsics, Albert F. Staettermayer, Matthias Pinter, Petra Steindl-Munda, Rainer Schoefl, Francesco Paolo Russo, Paolo Simioni, Michael Trauner, Peter Ferenci, Thomas Reiberger, Mattias Mandorfer
Summary: This study confirms the predictive value of noninvasive markers (LSM and VITRO) in determining the development of hepatic decompensation and hepatocellular carcinoma in patients with chronic liver disease caused by hepatitis C after cure. By combining these markers, it is possible to more accurately identify the risk of hepatic decompensation in patients in the future.
Article
Infectious Diseases
Yilihamu Abulitifu, Jiangshan Lian, Munire Adilijiang, Lan Liu, Fengcong Zhao, Wen Qian, Yongping Zhang
Summary: This study investigated the effectiveness and safety of sofosbuvir-velpatasvir (SOF/VEL) with and without ribavirin (RBV) in patients with genotype 3 (GT3) hepatitis C virus (HCV) infection-related cirrhosis from Xinjiang, China. The results showed that SOF/VEL, with or without RBV, was effective and safe for the treatment of GT3 HCV-associated cirrhosis.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Immunology
Timothy Papaluca, Stuart K. Roberts, Simone Strasser, Katherine A. Stuart, Geoffrey Farrell, Gerry MacQuillan, Gregory J. Dore, Amanda J. Wade, Jacob George, Simon Hazeldine, James O'Beirne, Alan Wigg, Leslie Fisher, Bruce McGarity, Rohit Sawhney, Marie Sinclair, James Thomas, Ivan Valiozis, Martin Weltman, Mark Wilson, Aidan Woodward, Golo Ahlenstiel, Mazhar Haque, Miriam Levy, Emily Prewett, William Sievert, Siddharth Sood, Edmund Tse, Zina Valaydon, Scott Bowden, Mark Douglas, Kate New, Jacinta O'Keefe, Margaret Hellard, Joseph Doyle, Mark Stoove, Alexander J. Thompson
Summary: This real-world study confirms the high efficacy of SOF/VEL/VOX for difficult-to-cure NS5A inhibitor experienced patients, particularly those with GT3 and cirrhosis, with an SVR12 rate of 85%. Treatment was generally well tolerated, but serious adverse events may occur in patients with advanced liver disease.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Gastroenterology & Hepatology
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Kuo-Chih Tseng, Ching-Chu Lo, Chun-Jen Liu, Jyh-Jou Chen, Cheng-Yuan Peng, Yu-Lueng Shih, Sheng-Shun Yang, Chia-Sheng Huang, Ke-Jhang Huang, Chi-Yang Chang, Ming-Chang Tsai, Wei-Yu Kao, Yo-Jen Fang, Po-Yueh Chen, Pei-Yuan Su, Chih-Wei Tseng, Jow-Jyh Huang, Pei-Lun Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chung-Hsin Chang, Yi-Jie Huang, Fu-Jen Lee, Chun-Chao Chang, Jia-Horng Kao
Summary: In patients with severe renal impairment and chronic hepatitis C virus infection, sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) for 12 weeks showed high effectiveness and safety, with high sustained virological response rates and minimal adverse events.
Article
Multidisciplinary Sciences
Liyu Chen, Lingyao Du, Shuang Kang, Fanghua Ma, Changmin Li, Min He, Lang Bai, Hong Tang
Summary: In Liangshan, China, people living with HIV have a high prevalence of HCV coinfection. A 24-week regimen of SOF+RBV can achieve good efficacy and is well-tolerated in this population. This treatment has the potential to be generalized in regions with limited resources.
SCIENTIFIC REPORTS
(2021)
Article
Virology
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hezode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Samuel
Summary: The study demonstrated that SOF/VEL plus RBV therapy for 12 weeks in patients with HCV-associated decompensated cirrhosis achieved high SVR12 rates and was generally well tolerated.
Article
Gastroenterology & Hepatology
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Chun-Jen Liu, Ching-Chu Lo, Ke-Jhang Huang, Jyh-Jou Chen, Kuo-Chih Tseng, Chi-Yang Chang, Cheng-Yuan Peng, Yu-Lueng Shih, Chia-Sheng Huang, Wei-Yu Kao, Sheng-Shun Yang, Ming-Chang Tsai, Jo-Hsuan Wu, Po-Yueh Chen, Pei-Yuan Su, Jow-Jyh Hwang, Yu-Jen Fang, Pei-Lun Lee, Chi-Wei Tseng, Fu-Jen Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chun-Chao Chang, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao
Summary: A study conducted in Taiwan showed that the treatment with SOF/VEL plus RBV for 12 weeks is highly effective and well-tolerated for patients with Child-Pugh B/C HCV-related cirrhosis. The SVR12 rates were outstanding, reaching 100%, and patients experienced improvements in liver and kidney function.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Hafiza Rida Farooq Chudhary, Amjad Ali, Sadia Bibi, Muhammad Waqas, Shazia Rafique, Muhammad Idrees, Sobia Ahsan Halim, Magda H. Abdellattif, Ajmal Khan, Ahmed Al-Harrasi
Summary: HCV is a global public health problem with a high number of infections worldwide. It is a leading cause of liver cancer due to the frequent occurrence of HCV infection, especially in those with HCV cirrhosis. This study analyzed the transcriptional analysis of the TP53 gene in HCV-infected patients treated with different antiviral therapies. The results showed that TP53 expression was significantly upregulated in patients with virological responses and HCC, and sofosbuvir + daclatasvir treatment had a significant impact on TP53 expression.
Article
Immunology
Akinbami Adenugba, Matthias Hornung, Kilian Weigand, Georg Peschel, Henrik Junger, Paul Kupke, Hauke Lang, Jens U. Marquardt, Tim Zimmermann, Edward K. Geissler, Hans J. Schlitt, Jens M. Werner
Summary: Chronic HCV infection is associated with NK cell activation and decreased IFN gamma production, with altered STAT1 and STAT4 phosphorylation. The addition of RBV to DAA therapy for HCV in LTx recipients enhances pSTAT4-dependent IFN gamma-production in NK cells.
Article
Gastroenterology & Hepatology
Guiseppe Indolfi, Deirdre Kelly, Gabriella Nebbia, Raffaele Iorio, Anna Mania, Vania Giacomet, Leszek Szenborn, Jiang Shao, Mun Sang Yue, Chia-Hsiang Hsueh, Bandita Parhy, Kathryn Kersey, Alessandra Mangia, Malgorzata Pawlowska, Sanjay Bansal
Summary: Sofosbuvir-velpatasvir-voxilaprevir is a highly effective and well-tolerated pangenotypic regimen for treating chronic HCV infection in adolescents aged 12 to 17 years.
Article
Spectroscopy
Sherif Ramzy, Ahmed H. Abdelazim
Summary: Simeprevir and sofosbuvir, direct-acting antiviral drugs for chronic HCV infection, may be considered as a combination therapy for COVID-19 due to similarities between HCV and SARS-CoV-2. This study developed two simple spectrophotometric methods for quantitative analysis of the drugs in combination.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
(2022)
Review
Gastroenterology & Hepatology
Lisa Sandmann, Heiner Wedemeyer
Summary: Interferon-alfa has been the main treatment for hepatitis D virus (HDV) infection, but only a portion of patients benefit from it. Successful interferon treatment is associated with improved long-term clinical outcomes. Although alternative treatments are being developed, pegylated interferon-alfa still plays an important role. There is a need for better biomarkers to select patients who are likely to benefit from interferon-based treatments.
LIVER INTERNATIONAL
(2023)
Article
Immunology
Oscar Brochado-Kith, Isidoro Martinez, Juan Berenguer, Juan Gonzalez-Garcia, Sergio Salguero, Daniel Sepulveda-Crespo, Cristina Diez, Victor Hontanon, Luis Ibanez-Samaniego, Leire Perez-Latorre, Amanda Fernandez-Rodriguez, Maria angeles Jimenez-Sousa, Salvador Resino
Summary: In HIV/HCV coinfected patients with advanced HCV-related cirrhosis, eradication of HCV following DAA therapy resulted in improved liver disease markers, decreased plasma biomarkers, and reduced gene expression related to antiviral/inflammatory responses, particularly in levels of chemokines and ISGs.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Lam Nhat Nguyen, Lam Ngoc Thao Nguyen, Juan Zhao, Madison Schank, Xindi Dang, Dechao Cao, Sushant Khanal, Bal Krishna Chand Thakuri, Jinyu Zhang, Zeyuan Lu, Xiao Y. Wu, Mohamed El Gazzar, Shunbin Ning, Ling Wang, Jonathan P. Moorman, Zhi Q. Yao
Summary: Chronic HCV infection leads to immune activation in CD4(+) T cells with reduced expression of stem cell-like transcription factor T cell factor 1 and telomeric repeat-binding factor 2 (TRF2). Hyperactivation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signaling on T cell receptor stimulation promotes inflammation and cellular damage, while inhibiting Akt signaling and enhancing TRF2 expression may provide therapeutic strategies.
Article
Virology
Toshifumi Tada, Masayuki Kurosaki, Shinichiro Nakamura, Chitomi Hasebe, Yuji Kojima, Koichiro Furuta, Haruhiko Kobashi, Hiroyuki Kimura, Chikara Ogawa, Hitoshi Yagisawa, Yasushi Uchida, Kouji Joko, Takehiro Akahane, Hirotaka Arai, Hiroyuki Marusawa, Ryoichi Narita, Yasushi Ide, Takashi Sato, Atsunori Kusakabe, Keiji Tsuji, Nami Mori, Masahiko Kondo, Akeri Mitsuda, Namiki Izumi
Summary: The study evaluated the efficacy and safety of sofosbuvir and velpatasvir interferon-free DAA therapy in HCV genotype 1- and 2-infected patients with decompensated cirrhosis. The results showed a high SVR rate of 92.3% and no severe adverse events, indicating that the SOF/VEL regimen is effective and safe in this patient population.
JOURNAL OF MEDICAL VIROLOGY
(2021)